Ferring Pharmaceuticals received authorization from the European Commission to market Firmagon, a prostate cancer drug. The treatment is a gonadotropin-releasing hormone receptor antagonist, indicated for patients with advanced, hormone-dependent prostate cancer. It is supplied as a powder to be reconstituted with sterile water for subcutaneous administration in the abdomen.

[ad]

The authorization follows degarelix’ FDA approval in December 2008.

In Phase III trials, Firmagnon reportedly reduced the levels of testosterone in more than 96% of patients within three days. Results were close to the immediate effect achieved with surgery, explains Ferring.

Source: GEN News

Popularity: 2% [?]